The study uses several cancer medicines, depending on the specific change found in the tumor. These include olaparib, erlotinib, crizotinib, trametinib, pemigatinib, selpercatinib, axitinib, vismodegib, pembrolizumab, larotrectinib, dabrafenib, and the injection Phesgo (trastuzumab and pertuzumab). Standard care medicines in the study include oxaliplatin, capecitabine, irinotecan, fluorouracil, calcium folinate, gemcitabine, and paclitaxel albumin-bound. Some medicines are taken by mouth, while others are given by injection or infusion into a vein.

During the study, people are assigned to receive either the tailored treatment or standard care. Treatment is given in repeated cycles, with regular medical visits to check health, side effects, and how the cancer is doing. The study follows people over time to see how long the cancer stays under control and how the treatments compare in safety and overall benefit.

The study is for people whose cancer has gotten worse after treatment with platinum-based chemotherapy and anti-PD-L1 or anti-PD-1 therapy, which are treatments that help the immune system fight cancer. Treatment of physician’s choice may include topotecan, tisotumab vedotin, irinotecan, pemetrexed, gemcitabine, or vinorelbine, and some medicines may be given with supportive care such as paracetamol, H2-receptor antagonists, and glucocorticoids to help reduce side effects. The study is randomized, which means treatment is assigned by chance, and it is open-label, which means both the study team and the participant know which treatment is being given.

The study has an initial part and then a larger comparison part. In the first part, MK-2870 is given to gather early information about how it acts in the body and how well it is tolerated. In the main part, MK-2870 is compared with other available cancer treatments. Treatment is given over time, with regular study visits and checks for side effects and general health while the cancer is being followed.

The purpose of the study is to determine if niraparib can help patients live longer without the disease getting worse, compared to temozolomide. Participants in the study will be randomly assigned to receive either niraparib or temozolomide. The study will monitor the participants over time to see how the treatments affect their health and the progression of their glioblastoma.

Throughout the study, researchers will also look at how the treatments impact overall survival, which means the length of time patients live after starting the treatment. Additionally, the study will assess the participants’ symptoms, quality of life, and any side effects they may experience. This information will help determine the safety and effectiveness of niraparib compared to temozolomide for treating this specific type of glioblastoma.

The purpose of the study is to see whether oral semaglutide can help slow worsening of memory, thinking, and daily function in people with early Alzheimer’s disease, and to check its safety. The study is randomised, which means the treatment is assigned by chance, and double-blind, which means neither the participants nor the study team knows who receives semaglutide or placebo during the study. Treatment is taken by mouth over a long period, and the study follows changes over time.

Participants take the study tablets regularly and are seen at planned visits during the trial. These visits are used to monitor health, review how the person is doing, and record any changes in memory, daily activities, or side effects. The study compares how people do over time in the semaglutide and placebo groups.

People in the study are assigned by chance to receive either inclisiran or placebo, and neither the participants nor the study team knows which one is given. The study follows participants over time while they receive the injections and are checked regularly for major heart-related problems such as myocardial infarction (heart attack), ischemic stroke (stroke caused by a blocked blood vessel), death from heart disease, or urgent procedures to open blocked heart arteries. The main purpose of the study is to find out whether inclisiran lowers the risk of these serious events better than placebo.

People in the study are placed into one of the treatment groups by chance. Treatment is given as intravenous infusion, which means medicine is delivered slowly through a vein. The study is planned to follow people over time while they receive treatment and after treatment ends to see how they do. The trial also watches for side effects, including cytokine release syndrome, a strong immune reaction, and ICANS, which is a group of brain and nerve symptoms that can happen with some immune treatments.

Obrixtamig is also known by the code name BI 764532. It is a type of treatment called a T cell engager, which is designed to help the immune system find and attack cancer cells that have DLL3 on their surface. The study is for previously untreated cancer that is DLL3-positive, meaning the cancer cells have this marker.

The purpose of the study is to see which medication provides better control of the disease after one year. Participants will receive their assigned medication regularly for up to 52 weeks, with scheduled doctor visits to check how they feel and to perform simple tests that look for signs of healing. The main goal is to determine whether patients achieve “deep remission,” meaning they have no symptoms and their intestinal lining looks normal.

The purpose of the study is to see if ziltivekimab works better than placebo in reducing the risk of serious heart-related problems in people who have both cardiovascular disease and kidney disease along with signs of inflammation in their body. The main focus is on preventing major cardiovascular events, which include death from heart-related causes, non-fatal heart attack, and non-fatal stroke. A heart attack occurs when blood flow to part of the heart muscle is blocked, while a stroke happens when blood flow to part of the brain is interrupted.

During the study, participants will receive either ziltivekimab or placebo through regular injections while continuing their standard medical treatment. The study will track various health outcomes over time, including heart attacks, strokes, heart-related deaths, hospital admissions for heart problems, and changes in kidney function. Researchers will also monitor changes in inflammation markers in the blood, heart function measurements, and overall health status. The study will measure how the kidneys are working by looking at blood test results that show the filtering ability of the kidneys and the amount of protein in the urine, which can indicate kidney damage.

The purpose of this research is to determine which medication provides better and safer conditions for placing the breathing tube in adult patients who need tracheal intubation during surgery. The study will look at how well each medication works and any possible side effects that may occur during or after the procedure.

During the study, patients will receive either remifentanil or rocuronium before the breathing tube is inserted. Doctors will monitor patients for any complications that might occur within 24 hours after the procedure, including effects on breathing, heart function, or discomfort in the throat. The medication doses are carefully calculated based on each patient’s weight, with remifentanil given at up to 4 micrograms per kilogram and rocuronium at up to 0.6 milligrams per kilogram.

The main goal is to assess the long‑term safety and tolerability of the medicine, meaning researchers will watch for any side effects or problems over an extended period. After the initial treatment period, participants will continue to attend regular visits where doctors will ask about health changes, perform a simple nasal examination, and may take a small blood sample to check drug levels. The study also records whether participants need additional treatments such as a short course of a systemic corticosteroid (a pill that reduces inflammation throughout the body) or sinus surgery.

At the start, pembrolizumab is given over a period of time, with regular medical checks during treatment. After treatment, the cancer is checked again with tests such as a CT scan, which is a special X-ray picture of the body, and an endoscopy, which is a thin tube test used to look inside the bowel. Based on these results, some people may go on to surgery, while others may be monitored closely without immediate surgery. The study also follows health over time to learn about possible side effects, recovery, and general well-being.

People in the study are assigned by chance to one of the two treatment groups, and neither the study team nor the participants know which treatment is being given. The treatment is taken as tablets over time, with regular study visits during the trial. During these visits, the study team checks for side effects and overall health, and asks about symptoms and daily well-being.

The trial is looking at adults with advanced kidney cancer who have already received treatment with PD-1/L1 and VEGF-TKI medicines, either one after the other or together. PD-1/L1 and VEGF-TKI are types of cancer medicines that act in different ways to slow tumor growth. The study follows participants while they receive treatment and for some time afterward to understand the effects of the medicine combination over time.

Adults who have had a kidney transplant are assigned to one of the study treatments. The study is randomized, which means the treatment is chosen by chance, and open-label, which means the treatment is known to the doctors and the participants. Frexalimab is given as an injection, while tacrolimus is taken by mouth as a capsule. The study follows participants for several years after transplantation to observe how the kidney is doing and to watch for signs of rejection, graft loss, death, and side effects.

During the study, regular checkups are done to monitor kidney function, general health, and possible unwanted effects of treatment. The study also looks at new health problems that can happen after a transplant, such as high blood pressure, abnormal blood fats, and diabetes. eGFR is one of the kidney tests used in the study; it is an estimate of how well the kidney is filtering the blood.

The treatment will involve receiving regular injections of the study medications for up to 52 weeks. Mirikizumab is a type of medication called a monoclonal antibody, which works by targeting specific parts of the immune system. Tirzepatide is a medication that can help with weight management. Some participants will receive both active medications, while others will receive Mirikizumab with placebo.

The study will measure how many participants achieve two goals at the same time: improvement in their Ulcerative Colitis symptoms and a significant reduction in their body weight. The medications will be given through injections either under the skin or into a vein, depending on the specific medication being administered.

The purpose of the study is to evaluate the effectiveness, safety, and tolerability of itepekimab in adults who have chronic rhinosinusitis with nasal polyps that are not well controlled. Participants in the study will receive either itepekimab or a placebo through an injection once a week for a total of 52 weeks, which is about one year. Throughout the study, participants will have regular check-ups to monitor their health and the effects of the treatment. The study aims to see if itepekimab can help reduce the symptoms of nasal polyps and improve the quality of life for those affected by this condition.

By participating in this study, researchers hope to gather important information about how itepekimab can help people with chronic rhinosinusitis with nasal polyps. This could lead to better treatment options in the future for those suffering from this condition. The study will also monitor any side effects or adverse reactions to ensure the safety of the participants. The results of this study could provide valuable insights into managing and treating chronic rhinosinusitis with nasal polyps more effectively.

Participants in the study will be randomly assigned to receive either BHV-7000 or a placebo, which looks like the medication but does not contain the active ingredient. The study will last for about eight weeks, during which participants will take the medication or placebo daily. Researchers will monitor the participants to see if there is a reduction in the number of seizures they experience. The goal is to find out if BHV-7000 can help reduce seizures by at least 50% in those taking the medication compared to those taking the placebo.

Throughout the study, the safety and tolerability of BHV-7000 will be closely observed. This means researchers will keep track of any side effects or adverse reactions participants might experience. The study aims to provide valuable information on whether BHV-7000 can be a beneficial treatment option for people with Refractory Focal Onset Epilepsy, potentially offering a new way to manage this challenging condition.

Participants in the study will receive either Barzolvolimab or a placebo, which is a substance that looks like the medication but does not contain any active ingredients. The study will last for several weeks, during which participants will receive regular doses of the medication or placebo. Throughout the study, participants will be monitored to assess changes in their urticaria symptoms, particularly focusing on the reduction of hives and itching. The main goal is to see if Barzolvolimab can significantly improve the condition compared to the placebo by the end of the study period.

The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication and who is receiving the placebo. This helps ensure that the results are unbiased and reliable. The trial will also involve regular check-ups and assessments to track the progress and any potential side effects. The findings from this study could provide valuable insights into the effectiveness of Barzolvolimab as a treatment option for those suffering from Chronic Spontaneous Urticaria.

The purpose of the study is to evaluate how well amlitelimab works in reducing the symptoms of atopic dermatitis and to assess its safety. Participants will receive the treatment over a period of 24 weeks. During this time, they will have regular check-ups to monitor their skin condition and overall health. The study aims to see if amlitelimab can help clear the skin or significantly reduce the severity of the symptoms compared to those who receive a placebo.

In addition to amlitelimab, the study will also involve the use of other topical treatments like tacrolimus and pimecrolimus, which are applied directly to the skin. These treatments are commonly used to manage atopic dermatitis by reducing inflammation and itching. The study will help determine the best approach to treating moderate-to-severe atopic dermatitis and provide valuable information on the potential benefits of amlitelimab for patients with this condition.

The purpose of the study is to evaluate how well Lebrikizumab works in reducing the severity of atopic dermatitis symptoms in both adults and adolescents. Participants will receive the treatment over a period of 24 weeks. During this time, they will have regular visits to monitor their condition and any changes in their symptoms. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of the treatment.

The study aims to see if Lebrikizumab can help improve the skin condition and overall quality of life for those with moderate-to-severe atopic dermatitis. Participants will be assessed on various aspects, such as the extent of skin improvement and relief from itching. The study will also look at how the treatment affects sleep and daily activities, providing a comprehensive view of its impact on the participants’ lives.

Participants in the study will be randomly assigned to receive either the MK-0616 tablet or a placebo, which looks like the real medication but does not contain the active ingredient. The study will monitor participants over a period to see if MK-0616 can help delay or prevent serious events such as heart attacks, strokes, or other cardiovascular complications. The study aims to understand if MK-0616 can increase the time before a participant experiences a major heart-related event.

Throughout the study, participants will continue their usual care and medications, and their health will be closely monitored by the research team. The study will also look at changes in cholesterol levels and other markers that are important for heart health. The goal is to gather information that could lead to better treatments for people with high cardiovascular risk due to ASCVD.

Participants in the study will receive either eneboparatide or a placebo for a period of 24 weeks. The treatment is administered through a pre-filled pen for subcutaneous injection, which means it is injected under the skin. The goal is to evaluate how effective eneboparatide is in reducing the need for active vitamin D and oral calcium supplements, and in maintaining normal serum calcium levels. The study will also assess changes in symptoms and physical functioning of the participants.

In addition to eneboparatide, the study involves other medications such as calcitriol and calcium carbonate, which are commonly used to manage calcium levels. Another medication, alfacalcidol, is also part of the study. These medications are used to help understand the overall effectiveness of the new treatment. The study aims to provide valuable information on the safety and benefits of eneboparatide for people living with chronic hypoparathyroidism.

The purpose of the study is to evaluate how well Povorcitinib works in reducing the symptoms of Hidradenitis Suppurativa and to monitor any side effects. The study will last for a period of up to 54 weeks, during which participants will take the medication in the form of oral tablets. Throughout the study, participants will have regular check-ups to assess their response to the treatment and any changes in their condition.

Participants will be monitored for improvements in their symptoms, such as a reduction in the number of painful lumps and overall skin condition. The study aims to provide valuable information on the potential benefits of Povorcitinib for individuals suffering from this challenging skin disease.

Participants in the study will be randomly assigned to receive either hydroxychloroquine sulfate or a placebo, which is a tablet that looks like the medication but does not contain any active ingredients. The study will monitor the participants throughout their pregnancy to observe any effects on pregnancy loss, premature birth, and other related outcomes. The medication will be taken orally in the form of film-coated tablets.

The trial will also assess the safety and tolerability of hydroxychloroquine sulfate for both the mother and the newborn. The study is expected to continue until the end of 2027, with participants being followed closely to gather comprehensive data on the effects of the treatment. The ultimate goal is to determine whether hydroxychloroquine sulfate can be a beneficial treatment option for improving pregnancy outcomes in women with antiphospholipid antibodies.

The purpose of the study is to evaluate the effectiveness and safety of Upadacitinib, which is a type of medication known as a Janus Kinase (Jak) 1 Inhibitor. This medication is taken orally in the form of a modified-release tablet, which means it is designed to release the active ingredient slowly over time. Participants in the study will receive either Upadacitinib or a placebo, which is a substance with no active medication, to compare the outcomes.

Throughout the study, participants will be monitored to see how their eczema symptoms change over time. The study will last for several months, and participants will have regular check-ups to assess their skin condition and overall health. The goal is to determine if Upadacitinib can significantly improve the symptoms of eczema and enhance the quality of life for those affected by this condition.

During the study, participants will receive either the active medication or a placebo. The treatment lasts for 48 weeks. While receiving the treatment, various observations will be made to monitor how the body responds and to check for any adverse events, which are unwanted or harmful medical occurrences. Monitoring includes checking vital signs, such as heart rate and blood pressure, and performing an electrocardiogram to check the electrical activity of the heart.

Participants in the study will receive medications through an intravenous infusion, which is a method of delivering medicine directly into a vein. The study involves comparing different combinations of drugs to see how they affect progression-free survival, a term used to describe the length of time during and after treatment that a person lives with the disease without it getting worse. Other factors being observed include overall survival and the quality of life, which tracks how well a person can perform daily activities and their general well-being during the study.

Participants in the study will receive either the IKT-001 film-coated tablet or a placebo. The study is designed in two parts to observe how the medication affects different aspects of the condition over a period of time. During the study, changes in pulmonary vascular resistance, which is the resistance to blood flow through the lung vessels, and the six-minute walk distance, which is a test measuring how far a person can walk in six minutes to assess physical capacity, will be monitored.

Participants in the study will receive mirikizumab through a subcutaneous injection, which is a method of delivering medication into the fatty layer of tissue just under the skin. During the course of the study, levels of the drug will be measured in breast milk to understand how much of the substance is present.

Participants in the study will receive the medication through an intravenous method, meaning it is delivered directly into a vein. One group will receive the drug through a bolus injection, which is a single, rapid dose given at specific times of the day. The other group will receive a continuous infusion, where the medication is delivered steadily over a period of time. This study aims to determine if the way the medicine is administered affects how well the body eliminates the excess fluid.

The purpose of the study is to find out if Trontinemab can slow down the worsening of symptoms in people with early Alzheimer’s Disease when compared to placebo. The study will measure this by looking at changes in thinking abilities, memory, and the ability to perform everyday tasks over a period of 72 weeks. Doctors will use various tests and rating scales to measure these changes, including tests that assess memory, thinking skills, and daily functioning. The study will also look at the safety of Trontinemab by monitoring any unwanted effects that may occur during treatment.

During the study, participants will receive either Trontinemab or placebo through an infusion into a vein. The study will last several years and will involve regular visits to the study site for medical examinations, blood tests, brain scans, and assessments of thinking and memory. Some participants will have additional brain scans using the imaging substances mentioned earlier to help doctors understand how the disease is affecting the brain and whether the treatment is having an effect on certain proteins that build up in the brains of people with Alzheimer’s Disease. Throughout the study, doctors will carefully monitor participants for any side effects and will perform various medical tests to ensure safety.

The purpose of the study is to see if trontinemab can slow down the worsening of symptoms in people with early Alzheimer’s Disease over a period of 72 weeks. During the study, people will receive either trontinemab or placebo through an infusion into a vein. The imaging substances will be given as injections to take special brain scans that show protein deposits linked to Alzheimer’s Disease. These scans help doctors understand what is happening in the brain.

Throughout the study, doctors will check how well people can think, remember things, and carry out everyday tasks using various tests and questionnaires. They will also monitor safety by checking for side effects, doing physical examinations, taking blood samples, and performing brain scans to look for any changes or problems. Some people in the study will have additional tests, including spinal fluid collection to measure certain proteins and extra brain scans to see tau protein, which is another substance that builds up in Alzheimer’s Disease. The study will measure changes in symptoms, brain protein levels, and overall safety of the treatment.

The purpose of this study is to find out if xaluritamig can help people live longer compared to the other treatment options. Xaluritamig is given as an infusion into a vein, which means it is delivered directly into the bloodstream through a needle. Some people in the study may also receive siltuximab, which is another medicine given through a vein that may help manage certain side effects. The study will also look at whether the cancer stops growing or shrinking, how long any improvements last, whether bone problems are delayed, and how the treatments affect pain and quality of life. Additionally, the study will monitor any unwanted effects or side effects that occur during treatment and will measure how the body processes xaluritamig and whether the body develops any immune response to it.

People joining this study will be randomly assigned to receive either xaluritamig or one of the other treatment options chosen by their doctor. Throughout the study, participants will have regular check-ups that include scans to see how the cancer is responding, blood tests to check overall health and levels of a substance called prostate-specific antigen, and questionnaires to understand how they are feeling and how the treatment is affecting their daily life. The study will continue for several years to gather enough information about how well the treatments work and how safe they are.

The purpose of the study is to see if this combination medication is safe for the heart and blood vessels and whether it can help prevent serious heart-related problems. The study will look at how many people experience major heart events such as heart-related death, heart attack, or stroke. The study will also look at changes in body weight, blood pressure, cholesterol levels, and blood sugar control. For people with diabetes, the study will check their HbA1c, which is a measure of average blood sugar over time.

During the study, people will receive weekly injections for up to several months. The study will collect information about any side effects and will measure various health markers through blood tests and physical examinations. The study will also assess quality of life, sleep quality, and pain levels. For people with diabetes, the study will monitor for episodes of very low blood sugar. The study will track kidney function by measuring eGFRcr, which shows how well the kidneys are filtering waste from the blood, and will check protein levels in urine. The study will continue until enough information is gathered to determine whether the medication is effective and safe.

The main goal of the study is to see how well CagriSema works at lowering blood sugar levels compared to semaglutide alone, as measured by a blood test called HbA1c that shows average blood sugar over several months. The study will also look at how these medications affect body weight, blood pressure, cholesterol levels, and other health measurements. Researchers want to understand if the combination medication works better than the individual medications at helping people reach target blood sugar levels and lose weight. The study will also measure how much time blood sugar levels stay within a healthy range using a continuous glucose monitor, which is a small device that tracks sugar levels throughout the day.

Participants will receive their assigned treatment for 68 weeks, with the entire study lasting about 75 weeks. During this time, they will have regular visits to check their blood sugar, weight, blood pressure, and overall health. The study will also ask participants questions about their quality of life and satisfaction with their diabetes treatment. Safety will be carefully monitored throughout the study, including checking for side effects and episodes of low blood sugar, which can occur when blood sugar drops too low and may cause symptoms like shakiness or confusion.

Participants in this study will be randomly assigned to receive either prednisolone or placebo for 10 days. The study is designed so that neither the participants nor the doctors will know who is receiving which treatment. To make the treatments look the same, the prednisolone tablets will be placed inside capsules. During the study, participants will be asked to complete questionnaires that measure dizziness and balance symptoms, as well as how these symptoms affect daily life and overall quality of life. These questionnaires will be completed at different times: 2 weeks, 6 weeks, 3 months, and 12 months after starting the treatment.

The study will also include tests to measure how well the balance system is working. These include a video test that measures eye movements when the head is moved quickly, a timed walking test, measurements of body movement while standing and walking, and a test of standing on a foam pad. Some of these tests will be done at the beginning of the study and again at 6 weeks to see if there are any changes. The main focus will be on comparing the dizziness symptom scores between the two groups at 6 weeks after treatment starts. The study will also look at healthcare use and time off work to understand the broader impact of the treatment.